Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H22FN3O3 |
Molecular Weight | 407.4375 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(OCC2(N)CC2)C=C3N=CC=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1
InChI
InChIKey=KSMZEXLVHXZPEF-UHFFFAOYSA-N
InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3
AL3818 (anlotinib) is a receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGFβ), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3). Anlotibib is a kind of innovative medicines approved by State Food and Drug Administration(SFDA:2011L00661) which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Phase III development is underway for the treatment of thyroid cancer, gastric cancer, leiomyosarcoma; non-small cell lung cancer; synovial sarcoma; thyroid cancer etc.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
0.2 nM [IC50] | |||
1.0 nM [IC50] | |||
7.7 null [pIC50] | |||
Target ID: CHEMBL4142 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27716285 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT03016819
Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28953502
AN3CA cells
appeared the most sensitive to AL3818 with an IC50 value of 84
nM. The other cell lines were approximately 28- to
550-fold less sensitive to AL3818. HEC1B had an IC50 value
of 46 uM, and MFE296 cells were sensitive to AL3818,
with an IC50 value of 2.9 uM compared with 3.2, 28.9, 29,
and 40 uM for Ishikawa, MFE280, KLE, and HEC1A, respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C129825
Created by
admin on Sat Dec 16 02:14:01 GMT 2023 , Edited by admin on Sat Dec 16 02:14:01 GMT 2023
|
||
|
FDA ORPHAN DRUG |
576017
Created by
admin on Sat Dec 16 02:14:01 GMT 2023 , Edited by admin on Sat Dec 16 02:14:01 GMT 2023
|
||
|
NCI_THESAURUS |
C1742
Created by
admin on Sat Dec 16 02:14:01 GMT 2023 , Edited by admin on Sat Dec 16 02:14:01 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB11885
Created by
admin on Sat Dec 16 02:14:01 GMT 2023 , Edited by admin on Sat Dec 16 02:14:01 GMT 2023
|
PRIMARY | |||
|
SUB192810
Created by
admin on Sat Dec 16 02:14:01 GMT 2023 , Edited by admin on Sat Dec 16 02:14:01 GMT 2023
|
PRIMARY | |||
|
C138997
Created by
admin on Sat Dec 16 02:14:01 GMT 2023 , Edited by admin on Sat Dec 16 02:14:01 GMT 2023
|
PRIMARY | |||
|
100000177425
Created by
admin on Sat Dec 16 02:14:01 GMT 2023 , Edited by admin on Sat Dec 16 02:14:01 GMT 2023
|
PRIMARY | |||
|
GKF8S4C432
Created by
admin on Sat Dec 16 02:14:01 GMT 2023 , Edited by admin on Sat Dec 16 02:14:01 GMT 2023
|
PRIMARY | |||
|
ANLOTINIB
Created by
admin on Sat Dec 16 02:14:01 GMT 2023 , Edited by admin on Sat Dec 16 02:14:01 GMT 2023
|
PRIMARY | Anlotinib (AL3818) - MedKoo CAT NO.: 206058Description: Anlotinib, alos known as AL3818, is a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, anlotininib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus). (Last update: 7/2/2015). Synonym: AL3818, AL-3818, AL 3818, Anlotinib - IUPAC/Chemical Name: NONE | ||
|
LM-10
Created by
admin on Sat Dec 16 02:14:01 GMT 2023 , Edited by admin on Sat Dec 16 02:14:01 GMT 2023
|
PRIMARY | |||
|
1058156-90-3
Created by
admin on Sat Dec 16 02:14:01 GMT 2023 , Edited by admin on Sat Dec 16 02:14:01 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545021
Created by
admin on Sat Dec 16 02:14:01 GMT 2023 , Edited by admin on Sat Dec 16 02:14:01 GMT 2023
|
PRIMARY | |||
|
25017411
Created by
admin on Sat Dec 16 02:14:01 GMT 2023 , Edited by admin on Sat Dec 16 02:14:01 GMT 2023
|
PRIMARY | |||
|
11077
Created by
admin on Sat Dec 16 02:14:01 GMT 2023 , Edited by admin on Sat Dec 16 02:14:01 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)